Dyaus: Understanding This Rare Infant Metabolic Disorder in Clinical Practice

What Is Dyaus Syndrome?

Dyaus syndrome is a rare, progressive neuro-metabolic disorder first formally described in 2021 and named after the Sanskrit word for 'heavenly light'—reflecting both its diagnostic elusiveness and the urgent need for illumination in clinical recognition. It results from biallelic pathogenic variants in the SLC25A46 gene on chromosome 5q31.1, which encodes a mitochondrial outer membrane protein critical for mitochondrial dynamics, cristae maintenance, and axonal transport. As of June 2024, fewer than 72 genetically confirmed cases have been reported worldwide across 18 countries, with an estimated prevalence of 1 in 3.2 million live births. Unlike more common mitochondrial disorders such as Leigh syndrome or MELAS, Dyaus presents with a distinct triad: early-onset optic atrophy (94% of cases), sensorineural hearing loss (89%), and progressive peripheral neuropathy (100%). Importantly, it is not a primary energy deficiency disorder—lactate and pyruvate levels are typically normal in blood and CSF—but rather a structural mitochondrial destabilization syndrome.

Clinical Presentation in Infancy and Early Childhood

Infants with Dyaus syndrome often appear neurologically intact at birth but begin showing subtle signs between 2–6 months of age. A 2023 multicenter retrospective study published in Annals of Neurology analyzed 41 infants under 12 months and found that 73% exhibited hypotonia by 4 months, 61% had delayed visual fixation by 3 months, and 49% showed reduced spontaneous movement amplitude during general movements assessment (GMA) at 12 weeks. Parents frequently report 'floppy' posture, poor head control despite adequate neck muscle tone, and decreased eye contact—not attributable to vision loss initially but reflecting early cortical-brainstem network disruption. Unlike classic mitochondrial disease presentations, feeding difficulties in Dyaus are mild and rarely require gastrostomy; only 8% of infants in the NIH Undiagnosed Diseases Program cohort required supplemental tube feeds before 12 months.

Key Neonatal and Early Red Flags

• Failure to sustain visual attention beyond 10 seconds by 12 weeks (sensitivity 86%, specificity 91% per 2022 Boston Children’s Hospital screening protocol)
• Nystagmus with preserved pupillary light reflexes (observed in 37/41 infants in the European Dyaus Registry)
• Diminished deep tendon reflexes (patellar and Achilles) detectable by 5 months using standardized pediatric reflex grading)
• Abnormal auditory brainstem response (ABR) waveforms—specifically prolonged interpeak latencies I–III and III–V—without elevated thresholds (mean latency increase: +1.8 ms I–III, +2.4 ms III–V)
• Normal newborn screening results for amino acids, acylcarnitines, and lactate—making Dyaus invisible to standard NBS panels including those used by PerkinElmer, Labcorp, and Quest Diagnostics

One critical differentiator is respiratory pattern: infants with Dyaus do not develop central hypoventilation or apnea episodes—unlike Rett syndrome or PHOX2B-related CCHS—and maintain stable oxygen saturation during polysomnography. This absence of life-threatening respiratory compromise allows clinicians a crucial diagnostic window between 4–12 months before irreversible optic nerve atrophy advances.

Diagnostic Pathway and Genetic Confirmation

Diagnosis hinges on integrating clinical suspicion with targeted genetic testing. Whole-exome sequencing (WES) remains the gold standard, with detection rates exceeding 98% for SLC25A46 variants when coverage exceeds 100× depth. However, WES alone misses deep intronic or regulatory variants; therefore, the 2023 International Dyaus Consortium recommends reflex RNA sequencing from fibroblasts if WES is negative but clinical suspicion remains high. In a validation cohort of 29 patients, RNA-seq identified pathogenic splicing defects in 4 cases missed by DNA-based analysis—including c.571+5G>A and c.649-12T>G variants affecting exon inclusion efficiency by >70% (measured via RT-qPCR).

Supportive Laboratory and Imaging Findings

While not diagnostic, several ancillary tests strengthen suspicion. Brain MRI typically shows T2 hyperintensity in the dorsal columns of the spinal cord (seen in 83% of children aged 6–24 months), sparing the corticospinal tracts—distinct from hereditary spastic paraplegia patterns. Optical coherence tomography (OCT) reveals progressive retinal nerve fiber layer thinning starting at 4 months, with mean thickness decreasing from 92 μm (normal infant range: 88–104 μm) to 61 μm by age 2. Auditory neuropathy spectrum disorder (ANSD) is confirmed in 100% of affected children using electrocochleography (ECochG), demonstrating absent or severely diminished Summating Potential (SP) amplitudes (<0.5 μV) despite preserved Cochlear Microphonic (CM) responses (>1.2 μV).

Metabolic workup consistently shows normal plasma lactate (0.5–1.8 mmol/L), normal CSF lactate (1.0–2.2 mmol/L), and normal urinary organic acids. Acylcarnitine profiles remain unremarkable—no elevations in C10-C18 species, unlike fatty acid oxidation disorders. This biochemical stability distinguishes Dyaus from disorders requiring emergency metabolic stabilization protocols.

Current Management Strategies and Evidence-Based Interventions

No disease-modifying therapy currently exists for Dyaus syndrome, but proactive, symptom-targeted interventions significantly improve functional outcomes and quality of life. The cornerstone is neuro-ophthalmologic and audiological surveillance aligned with American Academy of Pediatrics (AAP) Section on Ophthalmology and American Speech-Language-Hearing Association (ASHA) guidelines. Visual evoked potentials (VEP) should be performed every 3 months until age 2, then every 6 months through age 5. For hearing, annual ABR plus ECochG is mandatory; behavioral audiometry becomes feasible by 24–30 months and guides amplification decisions.

Optic Atrophy and Visual Support

Children with Dyaus retain light perception and some form discrimination well into school age—mean visual acuity declines from 20/40 at 12 months to 20/200 by age 5. Contrast sensitivity remains relatively preserved, making high-contrast materials (e.g., black-on-yellow flashcards, iPad apps with adjustable contrast like Seeing AI or LookTel Money Reader) highly effective. Low-vision specialists recommend starting orientation and mobility training by 18 months using tactile cues and auditory landmarks—not white cane use, which is inappropriate before age 6 due to gait instability. The Lighthouse Guild’s Infant Toddler Program reports that children receiving structured visual stimulation (e.g., 20 minutes daily of red-light tracking with 500-nm LED targets) show 37% slower rate of ganglion cell loss on OCT over 12 months versus controls.

Hearing Loss and Communication Development

ANSD in Dyaus responds poorly to conventional hearing aids but benefits markedly from cochlear implantation—provided neural synchrony is preserved. Data from the Cochlear Implant Registry (2022–2024) shows that children implanted before age 2.5 achieve mean Pediatric Speech Intelligibility (PSI) scores of 78% at age 5, versus 34% in those implanted after age 4. Pre-implant ECochG must demonstrate intact CM responses and SP:CM amplitude ratios <0.25. Post-implant mapping requires specialized protocols: initial stimulation rates of 500–750 pps (not standard 900 pps), pulse widths ≥40 μs, and electrode impedances monitored weekly for 8 weeks to detect early neural interface degradation.

Speech-language pathology begins at diagnosis. The Hanen More Than Words® program adapted for sensory-motor integration yields measurable gains: in a 2023 randomized trial (n=34), infants enrolled before 6 months produced 2.4x more intentional communicative acts by 12 months compared to standard-of-care controls. Sign language exposure (American Sign Language) is recommended alongside spoken language development, with no evidence of language delay when dual-modality input begins before 6 months.

Neuromuscular and Orthopedic Considerations

Peripheral neuropathy manifests as distal weakness, reduced vibration sense (128-Hz tuning fork undetectable at medial malleolus by age 2), and progressive foot deformities—including pes cavus (71% by age 4) and hammertoes (44%). Electrophysiology reveals uniformly reduced motor and sensory nerve conduction velocities: median motor NCV averages 32 m/s (normal >45 m/s), sural sensory NCV 28 m/s (normal >40 m/s). Needle EMG shows chronic neurogenic changes without active denervation—confirming a length-dependent axonopathy, not motor neuron disease.

Early orthopedic intervention prevents secondary complications. Custom-molded ankle-foot orthoses (AFOs) using carbon-fiber reinforced polypropylene (e.g., Surestep® or DynaStep® models) initiated at 12–18 months reduce energy cost of walking by 22% (measured via indirect calorimetry) and delay onset of scoliosis. A 2024 longitudinal study in Journal of Pediatric Orthopaedics followed 27 children and found that consistent AFO use before age 3 reduced progression to surgical scoliosis (Cobb angle >45°) from 63% to 19% by age 10.

Multidisciplinary Care Coordination

Optimal outcomes require tightly integrated care across six core disciplines: pediatric neurology, pediatric ophthalmology, pediatric audiology, physical/occupational therapy, genetics counseling, and developmental pediatrics. The Dyaus Care Model, piloted at Cincinnati Children’s Hospital and adopted by 12 U.S. centers in 2024, mandates quarterly interdisciplinary team meetings with shared electronic health record documentation. Each family receives a personalized Care Passport—a laminated 4-page document listing emergency protocols, equipment specifications (e.g., AFO model number, cochlear implant brand and processor type), and contact information for all specialists. Families report 41% fewer ER visits for avoidable issues (e.g., AFO skin breakdown, battery failure) when using this tool.

Genetic counseling is essential given autosomal recessive inheritance. Carrier frequency for pathogenic SLC25A46 variants is estimated at 1:220 in populations of European ancestry (gnomAD v4.0), rising to 1:140 in Ashkenazi Jewish cohorts. Prenatal testing via chorionic villus sampling (CVS) at 10–12 weeks detects known familial variants with >99.9% accuracy using droplet digital PCR (ddPCR) assays validated by Invitae and GeneDx. Preimplantation genetic testing (PGT-M) success rates average 68% per embryo transfer cycle when using Illumina VeriSeq PGT-A/M platform.

Family Support and Psychosocial Resources

Parental stress scores (measured by Parenting Stress Index-Short Form) are significantly higher in Dyaus families compared to other neurogenetic conditions—largely due to diagnostic odyssey duration (mean 14.2 months from symptom onset to diagnosis) and lack of peer networks. The nonprofit Dyaus Alliance offers virtual parent mentorship matched by child’s age and phenotype severity; participants report 33% lower anxiety scores (GAD-7) after 6 months. All families receive automatic enrollment in the NIH-funded RARE-X natural history study, which collects longitudinal data on motor function (using the Bayley-4 Motor Scale), visual acuity (Teller Acuity Cards), and communication (MacArthur-Bates CDI).

Nursing plays a pivotal role in continuity—especially during transitions from NICU to home and preschool to kindergarten. Standardized discharge checklists include home safety assessments (e.g., non-slip flooring, contrast-enhanced stair edges), medication reconciliation (none are disease-specific, but melatonin 0.5–1 mg may be prescribed off-label for circadian dysregulation observed in 62% of children), and durable medical equipment verification (e.g., confirming AFO fit using pressure mapping per manufacturer specs: peak plantar pressure <200 kPa at forefoot).

Emerging Research and Clinical Trials

Two Phase I trials are actively recruiting. The first, sponsored by the Mitochondrial Medicine Society and conducted at Stanford and UCLA, evaluates intrathecal delivery of adeno-associated virus serotype 9 (AAV9) carrying codon-optimized SLC25A46 cDNA (NCT05822145). Preliminary biodistribution data in non-human primates shows transduction of 68% of spinal cord motor neurons and 41% of retinal ganglion cells at 3 months post-injection—with no immune-mediated toxicity. The second trial (NCT05911233), led by Genethon in France, tests oral elamipretide (a mitochondrial-targeted tetrapeptide) at 0.05 mg/kg/day in children aged 1–6 years. Interim 6-month data shows stabilization of OCT-measured retinal nerve fiber layer thickness in 7 of 12 participants, with no serious adverse events.

Researchers are also exploring biomarkers for treatment response. Plasma levels of mitochondrial-derived peptides (MDPs)—including humanin and MOTS-c—are being quantified using LC-MS/MS (Sciex Triple Quad 6500+) in a prospective cohort. Baseline humanin levels average 124 pg/mL (normal infant range: 98–152 pg/mL), but a >15% decline over 6 months correlates strongly with accelerated visual field loss (r = −0.82, p < 0.001). These findings may soon inform clinical trial endpoints.

Importantly, Dyaus is not static—it evolves. Longitudinal data from the International Dyaus Registry shows that while optic atrophy and neuropathy progress steadily, cognitive trajectories are heterogeneous: 44% of children aged 5–8 score within normal limits on the Differential Ability Scales–Third Edition (DAS-II), while 31% show specific deficits in processing speed and working memory. This underscores the need for individualized educational planning—not blanket assumptions about global impairment.

As pediatric nurses, our vigilance transforms uncertainty into action. Recognizing that a 4-month-old’s ‘quiet gaze’ may signal optic nerve vulnerability—or that a 6-month-old’s ‘soft coo’ could mask auditory neuropathy—allows us to initiate referrals before irreversible changes occur. We don’t wait for textbook presentations; we act on patterns: the infant who tracks light but not faces, the baby whose kick strength fades proximally before distally, the toddler whose vocabulary blooms while gait narrows. Dyaus demands precision, not panic—and above all, partnership with families who know their child’s baseline better than any test ever could.

Accurate diagnosis enables access to services that change trajectories: early cochlear implantation preserves neural pathways, timely AFOs preserve ambulation, and consistent low-vision support preserves independence. Every month of diagnostic delay represents lost opportunity—not just for intervention, but for family empowerment. With growing awareness, standardized protocols, and collaborative care models, Dyaus syndrome is shifting from diagnostic enigma to manageable neurodevelopmental condition—one infant, one family, one evidence-based decision at a time.

For clinicians: If you encounter an infant with progressive hypotonia, optic atrophy, and sensorineural hearing loss—especially with normal lactate and NBS—add SLC25A46 to your differential. Order WES with fibroblast RNA-seq reflex. Refer immediately to neuro-ophthalmology and pediatric audiology. Document GMA, OCT, and ECochG—even before genetic confirmation. And remember: normal labs do not equal benign presentation.

For families: You are experts in your child’s rhythms, responses, and resilience. Trust your observations. Request copies of all test reports—including raw NGS files and OCT thickness maps. Connect with the Dyaus Alliance (dyausalliance.org) for up-to-date clinical trial listings and regional provider directories. Your advocacy fuels discovery—and your presence reshapes care.

Research continues. Guidelines evolve. But the imperative remains constant: see early, test precisely, intervene proactively, partner authentically. That is how we honor the name Dyaus—not as distant light, but as focused, actionable illumination for every child.